Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The antidepressant escitalopram likely caused hair loss in a patient.

In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This study presents two case reports where patients experienced hair loss during treatment with the SSRI sertraline, highlighting this rare but potential side effect.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This case study highlights the importance of early diagnosis and treatment of acneiform eruptions associated with erlotinib in a 67-year-old male patient with non-small cell lung cancer to ensure patient compliance.

This study found a significant association between montelukast and neuropsychiatric adverse events such as suicidal ideation and depression, suggesting that the drug's interaction with specific genes may contribute to these effects.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

This case report describes a 21-year-old male who experienced sertraline-induced diffuse hair loss that improved after discontinuing the medication.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

This letter to the editor discusses data from a study on troglitazone for lipodystrophy, noting significant increases in subcutaneous fat without dietary changes.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study found that treatment with Shunyou dispersible tablet and prednisone improved clinical symptoms in patients with lupus nephritis, showing significant benefits over time along with a good safety profile.